Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
暂无分享,去创建一个
Sanjiv J. Shah | D. DeMets | S. Solomon | J. McMurray | M. Vaduganathan | R. D. de Boer | S. Verma | Adrian F. Hernandez | C. Chiang | M. Kitakaze | B. Claggett | Yaling Han | D. Lindholm | B. Merkely | S. Inzucchi | J. Fang | M. Kosiborod | E. O'meara | F. Martinez | U. Wilderäng | C. Lam | O. Vardeny | C. J. Willem Borleffs | J. Thierer | J. Bělohlávek | J. Drożdż | D. Dobreanu | J. Comín-Colet | Magnus Petersson | S. Tereschenko | T. Katova | P. N. Vinh | Waleed Al Habeeb | M. Alcocer Gamba | Jose Walter Cabrera Honorio | S. Janssens | J. K. Kerr Saraiva | Natalia Zaozerska | Waleed Al habeeb | E. O’Meara | S. Verma | Rudolf A. de Boer
[1] P. Ponikowski,et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.
[2] G. Filippatos,et al. Empagliflozin and Major Renal Outcomes in Heart Failure. , 2021, New England Journal of Medicine.
[3] J. McMurray,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.
[4] S. Solomon,et al. Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week. , 2021, Journal of the American College of Cardiology.
[5] J. Butler,et al. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities. , 2021, Circulation.
[6] Sanjiv J. Shah,et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial , 2021, European journal of heart failure.
[7] J. Spertus,et al. Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction. , 2021, JAMA cardiology.
[8] P. Ponikowski,et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure , 2021, European journal of heart failure.
[9] G. Filippatos,et al. Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure , 2020, European journal of heart failure.
[10] P. Ponikowski,et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial , 2020, European journal of heart failure.
[11] Deepak L. Bhatt,et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.
[12] S. Solomon,et al. Global differences in heart failure with preserved ejection fraction: the paragon-hf trial , 2020 .
[13] D. Mann,et al. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. , 2020, Journal of the American College of Cardiology.
[14] Jacob P. Kelly,et al. Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). , 2020, The American journal of cardiology.
[15] Akshay S. Desai,et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure , 2019, Circulation.
[16] G. Filippatos,et al. Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial , 2019, European journal of heart failure.
[17] W. Shimizu,et al. Heart failure with preserved ejection fraction in Asia , 2018, European journal of heart failure.
[18] D. Atar,et al. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial , 2018, Circulation. Heart failure.
[19] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.
[20] Akshay S. Desai,et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. , 2016, European heart journal.
[21] A. di Lenarda,et al. Persistent Recovery of Normal Left Ventricular Function and Dimension in Idiopathic Dilated Cardiomyopathy During Long‐Term Follow‐up: Does Real Healing Exist? , 2015, Journal of the American Heart Association.
[22] B. French,et al. Heart Failure With Recovered Ejection Fraction: Clinical Description, Biomarkers, and Outcomes , 2014, Circulation.
[23] Akshay S. Desai,et al. Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial , 2013, Circulation. Heart failure.
[24] R. McKelvie,et al. Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I‐PRESERVE trial , 2008, European journal of heart failure.
[25] Karl Swedberg,et al. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.
[26] M. Pfeffer,et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme , 2003, European journal of heart failure.